| Ulcerative Colitis
Uceris vs Xeljanz
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Uceris vs Xeljanz with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXeljanz has a higher rate of injection site reactions vs Uceris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xeljanz but not Uceris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Uceris
Xeljanz
At A Glance
Rectal foam
Twice daily, then once daily
Glucocorticosteroid
Oral
Twice daily
JAK inhibitor
Indications
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Ulcerative Colitis
- Juvenile polyarthritis
Dosing
Ulcerative Colitis 1 metered dose administered rectally twice daily for 2 weeks, followed by 1 metered dose administered rectally once daily for 4 weeks.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis Adults: 5 mg twice daily (XELJANZ) or 11 mg once daily (XELJANZ XR).
Ulcerative Colitis Induction: 10 mg twice daily or 22 mg once daily for at least 8 weeks (up to 16 weeks); maintenance: 5 mg twice daily or 11 mg once daily.
Juvenile polyarthritis Weight-based dosing in pediatric patients >=2 years weighing >=10 kg; patients >=40 kg: 5 mg twice daily.
Contraindications
- History of known hypersensitivity to budesonide or any ingredient of UCERIS rectal foam, including anaphylaxis
—
Adverse Reactions
Most common (>=2%) Decreased blood cortisol, adrenal insufficiency, nausea
Serious Hypercorticism and adrenal axis suppression, steroid withdrawal symptoms, increased susceptibility to infection, other glucocorticosteroid effects
Postmarketing Hypertension, pancreatitis, pyrexia, peripheral edema, anaphylactic reactions, dizziness, benign intracranial hypertension, mood swings, pruritus, maculopapular rash, allergic dermatitis
Most common (>=2%) Upper respiratory tract infection, nasopharyngitis, diarrhea, headache, hypertension.
Serious Serious infections (pneumonia, cellulitis, herpes zoster, urinary tract infection), malignancy, thrombosis, major adverse cardiovascular events, gastrointestinal perforations.
Postmarketing Drug hypersensitivity (angioedema, urticaria), acne.
Pharmacology
Budesonide is a synthetic non-halogenated glucocorticosteroid that exerts local anti-inflammatory activity via glucocorticosteroid receptor binding; it undergoes extensive first-pass hepatic metabolism via CYP3A4, resulting in low systemic bioavailability.
Tofacitinib is a JAK inhibitor that blocks JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 signaling, preventing phosphorylation and activation of STATs to modulate immune cell function and hematopoiesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Uceris
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (9/12)
Xeljanz
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
UnitedHealthcare
Uceris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xeljanz
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (8/8)
Humana
Uceris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Xeljanz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Uceris.
No savings programs available for Xeljanz.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
UcerisView full Uceris profile
XeljanzView full Xeljanz profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.